Physician profile
Andrew C Rymill
NPI 1487107744
$4,922.09
in general payments reported to CMS, 2019-2025
27 companies · $1,007 in 2025
The $1,007 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $850 · 2022: $1,188 · 2023: $951 · 2024: $927 · 2025: $1,007.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,874 · Education: $10.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,874.29 |
| Education | $10.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,325.40 | 2021-2024 | Xifaxan, Trulance, Relistor |
| Abbvie INC. | $1,164.23 | 2021-2025 | |
| Janssen Biotech, INC. | $412.79 | 2022-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $371.92 | 2021-2025 | Entyvio, Gattex |
| Celgene Corporation | $294.39 | 2022-2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $253.09 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $167.30 | 2025 | Omvoh |
| Nestle Healthcare Nutrition INC. | $150.55 | 2021-2022 | |
| Ardelyx, INC. | $121.32 | 2022-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $70.07 | 2022-2024 | Dificid |
| Pfizer INC. | $65.75 | 2021-2024 | |
| Aimmune Therapeutics, INC. | $57.58 | 2024-2025 | Zenpep |
| Evoke Pharma, INC. | $54.59 | 2021-2024 | |
| Gilead Sciences, INC. | $53.18 | 2023 | |
| Intercept Pharmaceuticals, INC. | $48.61 | 2021-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mauna Kea Technologies, INC. | $42.99 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $38.96 | 2025 | Iqirvo |
| Tersera Therapeutics LLC | $36.09 | 2025 | Xermelo |
| Novo Nordisk INC | $33.68 | 2025 | Wegovy |
| Celltrion USA INC. | $29.10 | 2024-2025 | Vegzelma |
| Qol Medical, LLC | $25.42 | 2025 | Sucraid |
| Redhill Biopharma INC. | $23.96 | 2021-2022 | |
| Braintree Laboratories, INC. | $23.54 | 2021 | |
| Genzyme Corporation | $19.10 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.46 | 2023 | Cyltezo |
| Regeneron Healthcare Solutions, INC. | $13.54 | 2024 | Dupixent |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Rymill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.